MCRB — Seres Therapeutics, Inc.

Summary of MCRB Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Income: $8.2 million from continuing operations, a significant improvement from a net loss of $51 million in Q3 2024.
• Loss from Operations: $22.5 million, offset by a $27.2 million gain from the sale of VOWST, primarily due to a $25 million installment payment from Nestlé.
• R&D Expenses: Decreased to $12.6 million from $16.5 million in Q3 2024, attributed to lower personnel costs and reduced clinical expenses following the completion of the SER-155 Phase Ib study.
• G&A Expenses: Reduced to $9.5 million from $12.7 million in the prior year, mainly due to lower personnel and IT-related expenses.
• Cash Position: As of September 30, 2025, Seres had $47.6 million in cash and equivalents, with an expectation to fund operations through Q2 2026.

2. Strategic Updates and Business Highlights

• SER-155 Development: The lead investigational product is advancing into a Phase II study aimed at preventing bloodstream infections in adults undergoing allo-HSCT. Positive results could significantly enhance the company's value.
• FDA Engagement: Received constructive feedback on the SER-155 program, which has Breakthrough Therapy designation, aligning on key study parameters for the upcoming Phase II trial.
• CARB-X Grant: Secured a non-dilutive award of up to $3.6 million to support the development of an oral liquid formulation of SER-155, expanding access for vulnerable patient populations.
• Investigator-Sponsored Study: Ongoing study at Memorial Sloan Kettering evaluating SER-155 for immune-related enterocolitis, with initial results expected in early 2026.

3. Forward Guidance and Outlook

• Phase II Study: Anticipated initiation is dependent on securing funding, with meaningful interim analysis results expected within 12 months of study start.
• Expansion Potential: SER-155 has significant potential beyond allo-HSCT, targeting other medically vulnerable populations, representing a multibillion-dollar market opportunity.

4. Bad News, Challenges, or Points of Concern

• Funding Needs: The company is actively seeking capital to support the Phase II study and broader development activities, which remains a top priority.
• Workforce Reduction: Implemented a 25% workforce reduction to extend cash runway and focus on core priorities, indicating potential operational challenges.
• Market Competition: The company faces competitive pressures in the biotherapeutics space, particularly in addressing antimicrobial resistance and immune-related adverse events.

5. Notable Q&A Insights

• Study Design for irEC: The Phase I study at MSK is designed to assess safety and pharmacology of SER-155 in patients with immune checkpoint inhibitor-related enterocolitis, with results expected early 2026.
• Commercial Opportunity: The potential market for SER-155 in treating irEC is significant, given the high incidence of this side effect in patients receiving immune checkpoint inhibitors.
• Capital Acquisition: Management emphasized the importance of securing partnerships or alternative funding sources to support ongoing development, though specific capital needs were not disclosed.
• Nestlé Offer Rumors: Management refrained from commenting on rumors regarding a takeout offer from Nestlé, maintaining a policy of not discussing speculative reports.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by Seres Therapeutics, providing a balanced view of the company's current status and future outlook.